Title:
腫瘍を治療するためのパルボウイルス製剤
Document Type and Number:
Japanese Patent JP6423113
Kind Code:
B2
Abstract:
Described is a parvovirus formulation which comprises a pharmaceutically acceptable carrier having a viscosity between 3 to 5 mPa·s at 37 to 40°C. Preferably, the carrier is Visipaque 48% (in Ringer solution). A preferred use is therapy of a brain tumour by intratumoral injection.
Inventors:
Crepes, Ott Heinz
Dinzart, Christiane
Michael dharm
Ron Melal, Jean
Geretneky, Karsten
Leuchs, Barbara
Dinzart, Christiane
Michael dharm
Ron Melal, Jean
Geretneky, Karsten
Leuchs, Barbara
Application Number:
JP2017566665A
Publication Date:
November 14, 2018
Filing Date:
May 03, 2016
Export Citation:
Assignee:
DEUTSCHES KREBSFORSCHUNGSZENTRUM
Ruprecht-Karls-Universitaet Heidelberg
Ruprecht-Karls-Universitaet Heidelberg
International Classes:
A61K35/768; A61K47/02; A61K47/18; A61K47/24; A61K49/04; A61P35/00
Domestic Patent References:
| JP2013513358A |
Other References:
GELETNEKY K,BIOAVAILABILITY, BIODISTRIBUTION, AND CNS TOXICITY OF CLINICAL-GRADE PARVOVIRUS H1 AFTER 以下備考,COMPARATIVE MEDICINE,米国,AMERICAN ASSOCIATION FOR LABORATORY ANIMAL SCIENCE,2015年 2月,VOL:65, NR:1,PAGE(S):36 - 45,INTRAVENOUS AND INTRACEREBRAL INJECTION IN RATS,URL,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4396927/pdf/cm2015000036.pdf
GELETNEKY K,PATHOLOGY, ORGAN DISTRIBUTION, AND IMMUNE RESPONSE AFTER SINGLE AND REPEATED INTRAVENOUS 以下備考,COMPARATIVE MEDICINE,2015年 2月,VOL:65, NR:1,PAGE(S):23 - 35,INJECTION OF RATS WITH CLINICAL-GRADE PARVOVIRUS H1,URL,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4396926/pdf/cm2015000023.pdf
KARSTEN GELETNEKY,PHASE I/IIA STUDY OF INTRATUMORAL/INTRACEREBRAL OR INTRAVENOUS/INTRACEREBRAL 以下備考,BMC CANCER,英国,2012年 3月21日,VOL:12, NR:99,PAGE(S):1 - 9,ADMINISTRATION OF PARVOVIRUS H-1 (PARVORYX) IN PATIENTS WITH PROGRESSIVE PRIMARY OR 以下省略,URL,http://dx.doi.org/10.1186/1471-2407-12-99
GE HEALTHCARE,NEW ZEALAND DATASHEET,[ONLINE],2012年 4月30日,PAGE(S):1 - 15,URL,http://www.medsafe.govt.nz/profs/datasheet/v/visipaqueinj.pdf
GELETNEKY K,PATHOLOGY, ORGAN DISTRIBUTION, AND IMMUNE RESPONSE AFTER SINGLE AND REPEATED INTRAVENOUS 以下備考,COMPARATIVE MEDICINE,2015年 2月,VOL:65, NR:1,PAGE(S):23 - 35,INJECTION OF RATS WITH CLINICAL-GRADE PARVOVIRUS H1,URL,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4396926/pdf/cm2015000023.pdf
KARSTEN GELETNEKY,PHASE I/IIA STUDY OF INTRATUMORAL/INTRACEREBRAL OR INTRAVENOUS/INTRACEREBRAL 以下備考,BMC CANCER,英国,2012年 3月21日,VOL:12, NR:99,PAGE(S):1 - 9,ADMINISTRATION OF PARVOVIRUS H-1 (PARVORYX) IN PATIENTS WITH PROGRESSIVE PRIMARY OR 以下省略,URL,http://dx.doi.org/10.1186/1471-2407-12-99
GE HEALTHCARE,NEW ZEALAND DATASHEET,[ONLINE],2012年 4月30日,PAGE(S):1 - 15,URL,http://www.medsafe.govt.nz/profs/datasheet/v/visipaqueinj.pdf
Attorney, Agent or Firm:
Patent business corporation r&c